RxDoctor Payments Data

Louis Blumenfeld, MD

Pediatric Ophthalmology and Strabismus Specialist · Maitland, FLNPI 1396783130

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,336 of the $2,046 with a category attached, or 65.3%. Natus Medical Incorporated accounts for 65.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $1,508 and has fallen 98.7% since, to $19 in 2025.

$2,046in general payments, 2019–2025

Across 21 payments — averaging $97.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Natus Medical Incorporated$1K
  • Amgen$481
  • Santen Inc.$110
  • Sun Pharmaceutical Industries Inc.$44
  • Biotissue Holdings Inc.$24
  • Mallinckrodt Hospital Products Inc.$19
  • plus $31 from 2 others
$53,488in research payments, 2019–2025

Across 2 payments — averaging $26,744 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$53K

What the payments were for

  • Speaking & faculty fees$1,33665%
  • Food & beverage$69334%
  • Gifts$171%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Natus Medical Incorporated1$1,336
Amgen(2 entities)13$481
Santen Inc.1$110
Sun Pharmaceutical Industries Inc.2$44
Biotissue Holdings Inc.1$24
Mallinckrodt Hospital Products Inc.1$19
Carl Zeiss Meditec, Inc.1$17
Spark Therapeutics, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric ophthalmology and strabismus specialist providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$17,150
Medicare patients
61
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pediatric ophthalmology and strabismus specialist in Maitland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →